SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
Oxford University Press (United Kingdom) · University of Oxford
Abstract
Lowering low-density lipoprotein cholesterol with statin therapy results in substantial reductions in cardiovascular events, and larger reductions in cholesterol may produce larger benefits. In rare cases, myopathy occurs in association with statin therapy, especially when the statins are administered at higher doses and with certain other medications.
We carried out a genomewide association study using approximately 300,000 markers (and additional fine-mapping) in 85 subjects with definite or incipient myopathy and 90 controls, all of whom were taking 80 mg of simvastatin daily as part of a trial involving 12,000 participants. Replication was tested in a trial of 40 mg of simvastatin daily involving 20,000 participants.
Citation impact
- FWCI
- 76.20
- Percentile
- 100%
- References
- 27
Authors
1- TSThe SEARCH Collaborative GroupCorresponding
Oxford University Press (United Kingdom), University of Oxford
Topics & keywords
- Medicine
- SLCO1B1
- Statin
- Myopathy
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Internal medicine
- Cholesterol
- Pharmacogenetics
- Good health and well-being